[New trends in the search for nootropic preparations].
The paper describes the effects of the new nootropic agents nooglutyl and glycine N-phenyl-L-prolyl ethyl ester (GVS-111). Nooglutyl, a derivative of L-glutamic and oxynicotinic acids, that has glutamatergic effects is a highly active drug in treating disturbances of memory and learning, protecting against ischemic neuronal damage and brain injury. GVS-111 is a substituted prolyl dipeptide that has the properties of enhancing cognitive functions and is able to prevent the learning impairment provoked by shock, scopolamine, brain injury, and other damages. Multimodal mechanisms responsible for the nootropic effects of nooglutyl and GVS-111.
Voronina
T A
TA
D000647:Amnesia / Q000139:chemically induced / Q000188:drug therapy; D000818:Animals; D002545:Brain Ischemia / Q000188:drug therapy; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical; D004347:Drug Interactions; D006801:Humans; D009479:Neuropeptides / Q000494:pharmacology / Q000627:therapeutic use; D018697:Nootropic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D017470:Receptors, Glutamate / Q000187:drug effects
D009479:Neuropeptides; D018697:Nootropic Agents; D017470:Receptors, Glutamate